Venrock Adviser, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001615982

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2025 · 31 positions · Total reported value $1.33B · Top-10 concentration 74.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.1% · 4 new · 5 cut · 4 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +24.9% · vs SPY +10.0% · Prev Value $2.68B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2025 13F filing, Venrock Adviser, LLC disclosed 31 equity positions with a combined reported value of $1.33B. The filing implies a focused portfolio: its ten largest positions account for 74.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were APGE ($368.86M), OCUL ($118.44M), MTSR ($106.71M). By sector, the heaviest allocations are Health Care 54.7%, Materials 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+1.2pp) and away from Other (-1.1pp).

Versus the prior quarter, Venrock Adviser, LLC opened 4 new positions, trimmed 5 and fully exited 4, a turnover rate of 35.1% of positions. The portfolio's overlap with the prior quarter was 66% of names.

The largest new positions opened in Q2 2025 were JBIO ($32.17M), CTMX ($31.71M), CBIO ($22.40M).

Of the 4 positions fully exited versus the prior quarter, the largest were PRAX ($37.49M), SLDB ($9.18M), TRVI ($3.87M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • JBIO JADE BIOSCIENCES INC · $32.17M
  • CTMX CYTOMX THERAPEUTICS INC. · $31.71M
  • CBIO CRESCENT BIOPHARMA INC. · $22.40M
  • SEPN SEPTERNA INC · $5.71M

Fully Exited (vs previous quarter)

  • PRAX PRAXIS PRECISION MEDICINES I · prev qtr: $37.49M
  • SLDB SOLID BIOSCIENCES INC COM NEW · prev qtr: $9.18M
  • TRVI TREVI THERAPEUTICS INC · prev qtr: $3.87M
  • APLT APPLIED THERAPEUTICS INC · prev qtr: $2.72M
  • FDMT 4D MOLECULAR THERAPEUTICS IN · prev qtr: $2.19M
  • MRSN MERSANA THERAPEUTICS INC · prev qtr: $1.23M
  • IPSC CENTURY THERAPEUTICS INC · prev qtr: $1.19M · history
  • TNYA TENAYA THERAPEUTICS INC · prev qtr: $886.82K

Insider Transactions (Form 4)

Latest Venrock Adviser, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Venrock Adviser, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 33 US equity positions with a combined value of $3.30B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-79382 (status: Approved), registered 2014-04-09
  • Regulatory AUM (Form ADV): $4.50B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 1 hedge funds

Portfolio Structure

  • 33 positions · $3.30B reported value (Q2 2026)
  • Top 10 holdings = 80.4% of reported value
  • Largest position: APGE (APOGEE THERAPEUTICS INC) at 34.2%
  • Average position size: $99.94M

Sector Tilt

  • Health Care 65.7%
  • Financials 0.1%
  • (classified holdings cover 66% of value)

Quarterly Activity

  • Q2 2026: 4 new, 5 added, 5 reduced, 4 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 54.7%
Materials 0.1%
Other 45.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.49M $368.86M 27.64%
27.64%
Hold
2 12.76M $118.44M 8.88%
8.88%
Hold
3 3.75M $106.71M 8.00%
8.00%
Hold
4 4.03M $80.77M 6.05%
6.05%
Hold
5 6.73M $76.07M 5.70%
5.70%
Hold
6 6.60M $66.96M 5.02%
5.02%
Add
7 3.88M $54.28M 4.07%
4.07%
Hold
8 4.15M $46.50M 3.48%
3.48%
Hold
9 2.69M $40.20M 3.01%
3.01%
Hold
10 2.05M $36.04M 2.70%
2.70%
Reduce
11 4.76M $34.14M 2.56%
2.56%
Reduce
12 3.22M $32.17M 2.41%
2.41%
New
13 13.97M $31.71M 2.38%
2.38%
New
14 639.09K $31.13M 2.33%
2.33%
Reduce
15 2.30M $25.20M 1.89%
1.89%
Hold
16 17.86M $22.68M 1.70%
1.70%
Add
17 1.39M $22.40M 1.68%
1.68%
New
18 2.17M $20.70M 1.55%
1.55%
Hold
19 8.88M $20.26M 1.52%
1.52%
Add
20 1.00M $18.63M 1.40%
1.40%
Reduce
21 5.05M $18.37M 1.38%
1.38%
Hold
22 2.46M $13.17M 0.99%
0.99%
Hold
23 1.38M $10.39M 0.78%
0.78%
Hold
24 1.35M $10.30M 0.77%
0.77%
Hold
25 750.00K $7.96M 0.60%
0.60%
Hold
26 540.45K $5.71M 0.43%
0.43%
New
27 632.93K $5.66M 0.42%
0.42%
Hold
28 4.63M $4.86M 0.36%
0.36%
Reduce
29 1.61M $2.43M 0.18%
0.18%
Hold
30 987.26K $1.16M 0.09%
0.09%
Hold
31 98.56K $567.73K 0.04%
0.04%
Reduce

FAQ

What did Venrock Adviser, LLC buy in 2025-Q2?

In its 2025-Q2 13F filing, Venrock Adviser, LLC reported 31 equity positions worth $1.33B in aggregate; its largest disclosed positions were APGE ($368.86M), OCUL ($118.44M), MTSR ($106.71M).

How large is Venrock Adviser, LLC's portfolio?

Venrock Adviser, LLC reported $1.33B of long equity holdings across 31 positions as of 2025-Q2. Top-10 holdings account for 74.6% of reported value.

What is Venrock Adviser, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/venrock-adviser/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →